Internal Medicine Doctors in Chaska, MN Accepting Medicare
5 Internal Medicine doctors found. Showing 1 - 5
 Todd A Holcomb, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3000 Hundertmark Rd, Chaska, MN 55318 Phone: 952-556-0120 Fax: 952-556-0121 |
Sidney Amos Jones, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 111 Hundertmark Rd Ste 115n, Chaska, MN 55318 Phone: 952-361-2450 Fax: 952-361-2461 |
Dr. Ahsan M Bhatti, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1457 White Oak Dr, Chaska, MN 55318 Phone: 952-368-3800 Fax: 952-368-3801 |
 Dr. Purvi Gada, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 110105 Pioneer Trl W Ste 302, Chaska, MN 55318 Phone: 952-361-5800 Fax: 952-361-5858 |
Dr. Shaban Nazarian, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 111 Hundertmark Rd Ste 115n, Chaska, MN 55318 Phone: 952-361-2450 Fax: 952-361-2461 |
News Archive
ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).
Thrombospondin-1 contributes to development of aortic aneurysm in mice and humans, study finds
Researchers centered at the University of Tsukuba and Kansai Medical University in Japan reveal matricellular protein Thrombospondin-1 (Thbs1) contributes to the development of aortic aneurysm in mice and humans.
Metamark reports positive results from clinical validation study of prostate cancer prognostic test
Metamark Genetics, Inc., a privately-held biotechnology company, today announced positive results from a large clinical validation study of ProMark, its biopsy-based prostate cancer prognostic test.
FDA under scrutiny for appointment of 3 scientists with ties to industry
Fiscal Times looks at concerns about conflicts of interest on FDA advisory committees. Also, ProPublica examines a bill that would make results from NIH-financed studies harder to get.
› Verified 6 days ago
Family Medicine
Pediatrics
Internal Medicine
Endocrinology, Diabetes & Metabolism
Psychiatry & Neurology
Surgery
Gastroenterology